logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Editas Medicine: Business Highlights and Financial Results Reported

Editas Medicine Reporting Editas Medicine ( EDIT ) reported business highlights and financial results for the first quarter of 2021. The reporting started with James C. Mullen, Chairman, President and Chief Executive Officer, Editas Medicine stating that Editas’ team is...

Read More

May 5, 2021

0

Cassava Sciences: Significant Program Progress and its Expected Milestones for 2021

Cassava Sciences 2021 Focus and Momentum Cassava Sciences ( SAVA ) President & CEO, Remi Barbier, informed that the firm has started 2021 with tremendous momentum led by results of a 6-month interim analysis from an open-label study of simufilam...

Read More

February 8, 2021

0

Regenxbio, Moderna Therapeutics and Other Biotech Stocks Posted Gains in a Bad Market Day

Regenxbio, Moderna and Others Regenxbio ( RGNX ) announced several poster presentations including interim data from its Phase I/II trial of RGX-121 for the treatment of Mucopolysaccharidosis Type II ( MPS II ), and family surveys focused on patients with...

Read More

January 30, 2020

0

Why Cassava Sciences Stock Opened Down Today. See Also: The Mirati Therapeutics and MD Anderson Collaboration

Cassava Sciences Inc Opened Down Today Cassava Sciences, Inc. ( SAVA ) - a clinical-stage biotech firm focused on the treatment of Alzheimer’s disease, announced that it has entered into a definitive agreement with several healthcare-focused, and other institutional investors, for...

Read More

February 10, 2021

0

bluebird bio Temporarily Suspends Studies of LentiGlobin Gene Therapy for SCD. See Also: Cellectis is Outperforming

bluebird bio Suspends LentiGlobin Studies bluebird bio ( BLUE ) placed its Phase 1/2 (HGB-206) and Phase 3 (HGB-210) studies of LentiGlobin gene therapy for sickle cell disease (SCD), bb1111, on a temporary suspension due to a reported Suspected Unexpected Serious...

Read More

February 17, 2021

0

In a Market that Seems to Soar Today Our Eyes Are on These Biotech Firms

As the Market Seems to Soar Our Eyes Are on the Following Biotech Firms: Amgen ( AMGN ) : A rebounding is expected following an unwarranted decline.   Gilead Sciences ( GILD ) : A lot of good news from the...

Read More

February 4, 2020

0

Compugen: First Quarter Financial Results, Accomplishments and Future Plans

Compugen Updated Trial Data  Updated data from COM701 Phase 1 combination and monotherapy studies to be presented at the American Society of Clinical Oncology ( ASCO ) 2021 Annual Meeting Milestone rich 2021 to include data readouts from ongoing COM701...

Read More

May 13, 2021

0

Could Nektar Product NKTR-214 Become a Blockbuster?

Nektar Therapeutics NKTR-214: A Blockbuster? Nektar Therapeutics ( NKTR ) published preclinical data of its immuno-oncology candidate NKTR-214 bempegaldesleukin (bempeg) succeeded in revealing the details of the drug’s actions that led to its successful outcome when used in monotherapy or in...

Read More

February 4, 2020

0

A Synopsis of Some Biotech Companies' Events

Synopsis The way many bloggers are interpreting the quarterly and yearly biotech companies’ financial results seems unfair and has proven to be. Amgen Amgen ( AMGN ) : The stock gained over $10 yesterday and is trading now at $231....

Read More

February 6, 2020

0

An Important Agreement Between Bristol-Myers Squibb and Agenus

Bristol-Myers Squibb and Agenus Agreement for AGEN1777 Bristol-Myers Squibb ( BMY ) and Agenus ( AGEN ) today announced that they have entered into a definitive agreement under which Bristol Myers Squibb will be granted a global exclusive license to...

Read More

May 18, 2021

0

  • Previous
  • 1
  • 2
  • ...
  • 111
  • 112
  • 113
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy